<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327351</url>
  </required_header>
  <id_info>
    <org_study_id>TCRabPID-2012</org_study_id>
    <nct_id>NCT02327351</nct_id>
  </id_info>
  <brief_title>TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID</brief_title>
  <official_title>Phase II/III Study of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated and Haploidentical Donors After TCR Alfa Beta Negative Selection in Pediatric Patients With Primary Immunodeficiency Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment Study to assess of safety and efficiency of T cells receptor (TCR) alfa beta&#xD;
      depleted graft for hematopoietic stem cell transplantation (HSCT) from haploidentical and&#xD;
      unrelated donors in patients with primary immunodeficiency diseases&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infections, graft versus host diseases (GVHD) and associated morbidity and mortality remains&#xD;
      significant problems after unrelated and haploidentical hematopoietic stem sell&#xD;
      transplantation (HSCT) in patients with primary immunodeficiency diseases (PID). In this&#xD;
      study the hypothesis is that the transplantation of TCR alfa beta depleted peripheral blood&#xD;
      stem cells (PBSC) would offers advantages over the use of positively selected CD34+ stem&#xD;
      cells in haploidentical HSCT and non-manipulated graft in unrelated HSCT.&#xD;
&#xD;
      The purpose of this study is to evaluate the safety and efficiency of the selective infusion&#xD;
      of TCR alfa beta T cell depleted graft in pediatric patients with PID receiving HSCT from&#xD;
      haploidentical and unrelated donors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year after HSCT</time_frame>
    <description>The probability of overall survival estimated by the Kaplan-Meier method at 1 year after HSCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant Related Mortality (TRM)</measure>
    <time_frame>24 months after transplantation</time_frame>
    <description>transplant-related mortality estimated with cumulative incidence curve, considering relapse as a competitive risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft Versus Host Diseases (аGVHD)</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>incidence of aGVHD II-IV stage estimated with cumulative incidence curve, considering graft rejection and death as competitive risks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft Versus Host Diseases (cGVHD)</measure>
    <time_frame>1 year after HSCT</time_frame>
    <description>incidence of cGVHD estimated with cumulative incidence curve, considering graft rejection and death as competitive risks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular Immunological Reconstitution</measure>
    <time_frame>2 years after HSCT</time_frame>
    <description>Number of participants, who reached immune recovery - CD19+ lymphocytes subsets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Full Donor Chimerism</measure>
    <time_frame>last follow-up</time_frame>
    <description>Percentage of patients with full (more than 90%) donor chimerism among survivals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Infections After Transplant</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>number of patients with CMV reactivation (detection of any grade of CMV viremia after HSCT)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Primary Immune Deficiency Disorder</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>TCR alfa beta depletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological: TCR alfa beta T cell depletion</intervention_name>
    <arm_group_label>TCR alfa beta depletion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥ 1 months and &lt; 19 years&#xD;
&#xD;
          -  Patients diagnosed with Primary Immunodeficiency Diseases eligible for an allogeneic&#xD;
             transplantation and lacking a related HLA-matched donor&#xD;
&#xD;
          -  Lansky/Karnofsky score &gt; 40, WHO &gt; 4&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dysfunction of liver (ALT/AST &gt; 5 times normal value, or bilirubin &gt; 3 times normal&#xD;
             value), or of renal function (creatinine clearance &lt; 30 ml / min)&#xD;
&#xD;
          -  Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive&#xD;
             heart failure or left ventricular ejection fraction &lt;40%)&#xD;
&#xD;
          -  Serious concurrent uncontrolled medical disorder&#xD;
&#xD;
          -  Pregnant or breast feeding female patient&#xD;
&#xD;
          -  Lack of parents' informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexei Maschan, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dmitry Balashov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>February 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2021</results_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02327351/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TCR Alfa Beta Depletion</title>
          <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.&#xD;
Biological: TCR alfa beta T cell depletion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TCR Alfa Beta Depletion</title>
          <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.&#xD;
Biological: TCR alfa beta T cell depletion</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>The probability of overall survival estimated by the Kaplan-Meier method at 1 year after HSCT</description>
        <time_frame>1 year after HSCT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCR Alfa Beta Depletion</title>
            <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.&#xD;
Biological: TCR alfa beta T cell depletion</description>
          </group>
          <group group_id="O2">
            <title>Matched Unrelated Donor</title>
            <description>type of HSCT donor - HLA-matched unrelated donor</description>
          </group>
          <group group_id="O3">
            <title>HLA-mismatched Related Donor</title>
            <description>type of HSCT donor - HLA-mismatched related</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The probability of overall survival estimated by the Kaplan-Meier method at 1 year after HSCT</description>
          <units>percentage of survival probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="79" upper_limit="94"/>
                    <measurement group_id="O2" value="86" lower_limit="79" upper_limit="94"/>
                    <measurement group_id="O3" value="87" lower_limit="73" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Gray test</method>
            <param_type>survival distribution function</param_type>
            <param_value>86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79</ci_lower_limit>
            <ci_upper_limit>94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant Related Mortality (TRM)</title>
        <description>transplant-related mortality estimated with cumulative incidence curve, considering relapse as a competitive risk</description>
        <time_frame>24 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCR Alfa Beta Depletion</title>
            <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.&#xD;
Biological: TCR alfa beta T cell depletion</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant Related Mortality (TRM)</title>
          <description>transplant-related mortality estimated with cumulative incidence curve, considering relapse as a competitive risk</description>
          <units>percentage of cumulative incidence</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="6" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft Versus Host Diseases (аGVHD)</title>
        <description>incidence of aGVHD II-IV stage estimated with cumulative incidence curve, considering graft rejection and death as competitive risks</description>
        <time_frame>12 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCR Alfa Beta Depletion</title>
            <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.&#xD;
Biological: TCR alfa beta T cell depletion</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft Versus Host Diseases (аGVHD)</title>
          <description>incidence of aGVHD II-IV stage estimated with cumulative incidence curve, considering graft rejection and death as competitive risks</description>
          <units>percentage of cumulative incidence</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="1" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Graft Versus Host Diseases (cGVHD)</title>
        <description>incidence of cGVHD estimated with cumulative incidence curve, considering graft rejection and death as competitive risks</description>
        <time_frame>1 year after HSCT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TCR Alfa Beta Depletion</title>
            <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.&#xD;
Biological: TCR alfa beta T cell depletion</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Graft Versus Host Diseases (cGVHD)</title>
          <description>incidence of cGVHD estimated with cumulative incidence curve, considering graft rejection and death as competitive risks</description>
          <units>percentage of cumulative incidence</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cellular Immunological Reconstitution</title>
        <description>Number of participants, who reached immune recovery - CD19+ lymphocytes subsets</description>
        <time_frame>2 years after HSCT</time_frame>
        <population>alive at a time-point 2 years after HSCT</population>
        <group_list>
          <group group_id="O1">
            <title>TCR Alfa Beta Depletion</title>
            <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.&#xD;
Biological: TCR alfa beta T cell depletion</description>
          </group>
        </group_list>
        <measure>
          <title>Cellular Immunological Reconstitution</title>
          <description>Number of participants, who reached immune recovery - CD19+ lymphocytes subsets</description>
          <population>alive at a time-point 2 years after HSCT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Full Donor Chimerism</title>
        <description>Percentage of patients with full (more than 90%) donor chimerism among survivals</description>
        <time_frame>last follow-up</time_frame>
        <population>survivals at the last folow-up</population>
        <group_list>
          <group group_id="O1">
            <title>TCR Alfa Beta Depletion</title>
            <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.&#xD;
Biological: TCR alfa beta T cell depletion</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Full Donor Chimerism</title>
          <description>Percentage of patients with full (more than 90%) donor chimerism among survivals</description>
          <population>survivals at the last folow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Infections After Transplant</title>
        <description>number of patients with CMV reactivation (detection of any grade of CMV viremia after HSCT)</description>
        <time_frame>12 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Matched Unrelated Donor</title>
            <description>donor type - HLA-matched unrelated donor</description>
          </group>
          <group group_id="O2">
            <title>Mismatched Related Donors</title>
            <description>donor type - HLA-mismatch relative</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Infections After Transplant</title>
          <description>number of patients with CMV reactivation (detection of any grade of CMV viremia after HSCT)</description>
          <units>percentage of cumulative incidence</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="38" upper_limit="65"/>
                    <measurement group_id="O2" value="60" lower_limit="42" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TCR Alfa Beta Depletion</title>
          <description>TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.&#xD;
Biological: TCR alfa beta T cell depletion</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ADV hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>TMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CMV pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Balashov Dmitriy, head of HSCT department</name_or_title>
      <organization>National Research Center for Pediatric Hematology , Moscow, Russian Federation</organization>
      <phone>84956647078 ext 6534</phone>
      <email>Dmitriy.Balashov@fccho-moscow.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

